Last reviewed · How we verify
ZIPRASIDONE
ZIPRASIDONE is a drug. It is currently FDA-approved (first approved 2001).
Ziprasidone's mechanism of action involves antagonizing dopamine D2 and serotonin 5HT2 receptors.
Ziprasidone is used to treat psychotic disorders, including psychosis, agitation, delirium, and schizophrenia. It is administered orally and has been studied in clinical trials as a treatment for patients who have already shown benefits from previous ziprasidone treatment.
At a glance
| Generic name | ZIPRASIDONE |
|---|---|
| Target | dopamine D2, serotonin 5HT2 |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2001 |
Mechanism of action
Ziprasidone works by blocking dopamine D2 and serotonin 5HT2 receptors, which helps to modulate neurotransmitter activity in the brain. This dual action is thought to contribute to its therapeutic effects in treating various psychiatric conditions.
Approved indications
Boxed warnings
- WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1)] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone is not approved for the treatment of patients with dementia-related psychosis ( 5.1 )
Common side effects
Key clinical trials
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes (PHASE3)
- Maternal And Infant Antipsychotic Study
- A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
- Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia (PHASE1)
- Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD) (PHASE4)
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
- Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZIPRASIDONE CI brief — competitive landscape report
- ZIPRASIDONE updates RSS · CI watch RSS
Frequently asked questions about ZIPRASIDONE
What is ZIPRASIDONE?
How does ZIPRASIDONE work?
When was ZIPRASIDONE approved?
What development phase is ZIPRASIDONE in?
What does ZIPRASIDONE target?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing